Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

IPACK vs Adductor Magnus Plane Block Added to Adductor Canal Block for Total Knee Arthroplasty

10 juni 2026 bijgewerkt door: Ahmet Murat Yayik, Ataturk University

Comparison of the Effectiveness of IPACK Block Versus Adductor Magnus Muscle Plane Block When Combined With Adductor Canal Block in Total Knee Arthroplasty Surgery

Total knee arthroplasty (TKA) is among the most frequently performed surgical procedures for degenerative joint diseases, including advanced knee osteoarthritis, rheumatoid arthritis, and post-traumatic arthritis. More than 700,000 TKA procedures are performed annually in the United States alone since 2012, with projections estimating a 143% increase by 2050. A significant proportion of patients experience moderate to severe postoperative pain following the procedure, adversely affecting early mobilization, adherence to rehabilitation programs, and ultimately functional recovery .

Femoral nerve block (FNB) was historically the cornerstone of TKA analgesia; however, concerns about quadriceps weakness and associated fall risk led to its replacement by more motor-sparing alternatives . Adductor canal block (ACB) has since become the standard approach, providing analgesia equivalent to FNB while significantly preserving quadriceps strength . Nevertheless, ACB does not adequately cover the posterior capsule and popliteal plexus terminals; consequently, 60-80% of TKA patients report significant posterior knee pain that cannot be sufficiently managed by ACB alone .

To address this limitation, several posterior knee analgesia techniques have been described. The IPACK (Interspace between Popliteal Artery and Capsule of the Knee) block targets genicular nerve branches and popliteal plexus terminals by injecting local anesthetic between the popliteal artery and the posterior knee capsule, largely sparing the main motor trunks and providing selective posterior analgesia . The adductor magnus muscle plane (AMM) block is a relatively novel interfascial plane block technique applicable in the supine position simultaneously with ACB. By injecting local anesthetic into the fascial plane along the posterior surface of the adductor magnus muscle, the AMM block aims to spread to the popliteal plexus and posterior capsular branches, potentially mimicking a sciatic nerve block effect . A key advantage of the AMM block is its applicability without patient repositioning during the same session as ACB.

The primary objective of this prospective randomized trial was to compare the effects of IPACK and AMM blocks-both added to ACB-on postoperative opioid consumption in patients undergoing TKA. Secondary objectives included evaluating the impact of each technique on postoperative pain scores, mobilization time, functional recovery, and motor function

Studie Overzicht

Gedetailleerde beschrijving

Study Design and Ethical Approval This prospective, randomized, parallel-group trial was approved by the Ethics Committee of Atatürk University Faculty of Medicine (Decision No. 5, Meeting No. 7, dated October 26, 2023). Written informed consent was obtained from all participants before enrollment.

Patients aged 18-75 years with American Society of Anesthesiologists (ASA) physical status I-III scheduled for primary total knee arthroplasty (TKA) were eligible. Exclusion criteria included hepatic, renal, or advanced cardiac insufficiency; neuropathic pain; use of analgesics within 24 hours before surgery; coagulopathy or anticoagulant therapy; advanced cardiovascular disease; allergy to study medications; inability to cooperate; chronic opioid use; and previous lumbar instrumentation.

Of 90 patients assessed for eligibility, 30 were excluded because of chronic renal failure (n = 3), chronic opioid use (n = 5), anticoagulant therapy (n = 8), inability to cooperate (n = 10), or L2-L4 vertebral instrumentation (n = 4). Sixty patients were included and randomized equally into two groups: IPACK (n = 30) and AMM (n = 30).

Randomization and Blinding Participants were randomized in a 1:1 ratio using a computer-generated randomization sequence one hour before surgery. Allocation assignments were concealed in sealed opaque envelopes and delivered to the operating room technician responsible for preparing the intervention.

The anesthesiologist performing the regional block could not be blinded because of the procedural differences. However, patients, surgeons, and the investigator responsible for postoperative outcome assessment were blinded to group allocation.

Regional Anesthesia Procedures ACB Block All patients received an ultrasound-guided adductor canal block (ACB) combined with either an infiltration between the popliteal artery and capsule of the knee (IPACK) block or an adductor magnus muscle plane (AMM) block.

For the ACB, patients were positioned supine with slight external rotation of the hip. After ultrasound identification of the adductor canal, correct needle placement was confirmed with 2 mL of 0.9% saline, followed by injection of 10 mL of 0.5% bupivacaine diluted with 10 mL of 0.9% saline. Dermatomal sensory assessment was performed 5 minutes after injection.

IPACK Block With the patient supine and the knee slightly externally rotated, the ultrasound transducer was placed transversely on the medial aspect of the distal thigh. After identifying the distal femur and popliteal artery, the needle was advanced in-plane into the interspace between the popliteal artery and femur. Following negative aspiration and saline confirmation, 10 mL of 0.5% bupivacaine and 10 mL of saline were injected with intermittent aspiration every 5 mL.

AMM Block The transducer was positioned medially over the distal thigh to identify the adductor muscle compartment. The needle was advanced in-plane from anteromedial to posterolateral until a fascial "pop" indicated entry into the posterior compartment. After negative aspiration and saline confirmation, 10 mL of 0.5% bupivacaine and 10 mL of saline were administered. In the AMM group, the subsequent ACB was performed through needle redirection without a second skin puncture.

For all procedures, needle tip visibility, needle shaft visibility, number of needle insertions, and block performance time were recorded. Dermatomal coverage of the tibial, common peroneal, sural, saphenous, and posterior femoral cutaneous nerves was assessed at 5, 10, 15, 20, 30, and 45 minutes after block placement.

Anesthetic Management Standard monitoring, including electrocardiography, pulse oximetry, and noninvasive blood pressure monitoring, was applied in the operating room. Before spinal anesthesia, patients received intravenous midazolam 2 mg, ondansetron 8 mg, and dexamethasone 8 mg.

Spinal anesthesia was performed under sterile conditions at the L3-L4 or L4-L5 interspace using a 25-gauge spinal needle. Following confirmation of cerebrospinal fluid flow, 15 mg hyperbaric bupivacaine was administered intrathecally. Surgery commenced after a sensory block level of T10 was achieved.

Surgical Technique All TKAs were performed under spinal anesthesia using a standard medial parapatellar approach. After exposure of the knee joint, the anterior cruciate ligament and osteophytes were removed, and femoral and tibial bone cuts were performed using standard alignment guides. Trial components were inserted to assess fit, alignment, stability, and range of motion. Final femoral, tibial, and polyethylene components were implanted using a cemented technique with one package of bone cement.

A negative-pressure intra-articular drain was placed before layered wound closure. The procedure concluded with application of a Jones compression bandage.

Perioperative Analgesia Paracetamol 1 g was administered intravenously 30 minutes before completion of surgery and continued every 8 hours postoperatively. Dexketoprofen trometamol 25 mg was administered intraoperatively 30 minutes before the end of surgery and continued every 12 hours postoperatively.

Postoperative analgesia was provided using intravenous patient-controlled analgesia (PCA) with fentanyl (10 µg/mL concentration, 25 µg bolus dose, 15-minute lockout interval, 48-hour duration). In addition, all patients received paracetamol 1 g three times daily and dexketoprofen 25 mg twice daily as part of a multimodal analgesic regimen.

Patients with a visual analog scale (VAS) score ≥ 4 in the recovery room received rescue tramadol 100 mg intravenously. Patients achieving an Aldrete score ≥ 9 were transferred to the ward.

Outcome Measures The primary outcome was postoperative opioid consumption. Secondary outcomes included postoperative pain scores, motor function, mobilization, and functional recovery.

VAS pain scores and adverse events were recorded at 1, 2, 4, 8, 12, 24, and 48 hours postoperatively. Opioid consumption was assessed during the 0-4, 4-8, and 8-24 hour intervals and as a cumulative 24-hour total.

Motor block of the quadriceps femoris and tibialis anterior muscles was evaluated using a three-point scale (0 = paralysis, 1 = paresis, 2 = normal strength) immediately after surgery and at 12, 24, and 48 hours.

Preoperative assessments included walking aid use, presence of varus-valgus deformity, anterior and posterior VAS scores, Timed Up and Go (TUG) test, quadriceps muscle strength, and active range of motion (ROM). The TUG test measured the time required to stand from a chair, walk 3 meters, return, and sit down. Quadriceps strength was assessed isometrically, and active ROM was measured using a goniometer.

On postoperative days 1 and 2, mobilization time, VAS scores, TUG performance, quadriceps strength, ROM, and the Five Times Sit-to-Stand Test (FTSST) were recorded.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

60

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Ja

Beschrijving

Inclusion Criteria:

  • Anesthesiologists (ASA) physical status I-II-III
  • Total Knee Arthroplasty Surgery

Exclusion Criteria:

  • cardiovascular disease,
  • hepatic dysfunction,
  • coagulopathy or current use of anticoagulant therapy,
  • inability to cooperate,
  • known allergy to any of the study medications,
  • refusal to participate in the study

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: ACB+IPACK
Participants in this arm will receive an ultrasound-guided adductor canal block (20 mL of 0.25% bupivacaine) and IPACK block (20 mL of 0.25% bupivacaine) before surgery. Blocks will be performed under sterile ultrasound guidance by an experienced anesthesiologist who will not participate in postoperative assessments. All patients will receive standardized spinal anesthesia and perioperative analgesia

With the patients in the supine position and the knee slightly externally rotated, the ultrasound transducer will be placed transversely on the medial aspect of the knee, approximately 2-3 cm above the patella. After identifying the distal femoral shaft and the popliteal artery, the needle will be advanced in-plane in an anteromedial direction toward the space between the popliteal artery and the femur. Following negative aspiration and confirmation with normal saline, 10 mL of 0.5% bupivacaine and 10 mL of 0.9% NaCl will be administered, with aspiration performed every 5 mL.

Needle tip visibility, needle shaft visibility, number of needle insertions, and block duration will be recorded for all procedures.

Dermatomal spread of the tibial, peroneal, sural, saphenous, and posterior femoral cutaneous nerves (PFCN) will be assessed at predefined time points: 5, 10, 15, 20, 30, and 45 minutes after block administration.

Actieve vergelijker: ACB+AMM
Adductor Canal + Adductor Magnus Muscle Plane block: Participants in this arm will receive an ultrasound-guided anterior sciatic nerve block (20 mL of 0.25% bupivacaine) and an adductor canal block (20 mL of 0.25% bupivacaine) before surgery. Blocks will be performed under sterile ultrasound guidance by an experienced anesthesiologist who will not participate in postoperative assessments. All patients will receive standardized spinal anesthesia and perioperative analgesia.
With patients supine and the leg slightly abducted and externally rotated, the ultrasound probe will be placed 10-15 cm distal to the inguinal crease and moved medially to visualize the adductor muscles. The needle will be advanced in-plane from anteromedial to posterolateral, avoiding the femoral vessels and obturator nerve, until a fascial "pop" indicates entry into the posterior compartment. After negative aspiration and saline confirmation, 10 mL of 0.5% bupivacaine and 10 mL of 0.9% NaCl will be injected. In the AMM group, the adductor canal block will be performed by redirecting the same needle without a second puncture; in the IPACK group, a separate insertion will be used. Dermatomal spread will be assessed at 5, 10, 15, 20, 30, and 45 minutes after block administration.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Opioid consumption
Tijdsspanne: [Time Frame: 0-4 hours, 4-8 hours, 8-24 hours, Total 24-hour]
Postoperative opioid consumption
[Time Frame: 0-4 hours, 4-8 hours, 8-24 hours, Total 24-hour]

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Pain Scores (VAS) at Rest and During Movement
Tijdsspanne: [Time Frame: PACU, 1st hour, 2nd hours, 4th hours, 8th hours, 12th hours, 24th hours,48th hours,]

Pain intensity will be evaluated using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst pain).

Assessments will be performed at rest and during movement at predefined postoperative time points.

[Time Frame: PACU, 1st hour, 2nd hours, 4th hours, 8th hours, 12th hours, 24th hours,48th hours,]
Adverse Effects
Tijdsspanne: [Time Frame: up to 24 hours]
Opioid-Related Adverse Effects
[Time Frame: up to 24 hours]
Evaluation of Nerve Blockade after Nerve Block Application
Tijdsspanne: [Time Frame: 5., 10., 15., 20., 30., and 45. minutes]

Post-block sensory assessment was performed at predefined time intervals using a cold-warm discrimination test.

Sensory evaluation was conducted at the plantar surface of the foot for the tibial nerve, the dorsal surface of the foot for the superficial peroneal nerve, the posterolateral aspect of the leg for the sural nerve, the posterior aspect of the thigh for the posterior femoral cutaneous nerve, and at the medial malleolus for the saphenous nerve.

[Time Frame: 5., 10., 15., 20., 30., and 45. minutes]
Quadriceps and Anterior Tibialis Muscle Strength
Tijdsspanne: [Time Frame: 4th hours, 8th hours, 12th hours, 24th hours, 48th hours]
Muscle strength will be assessed using standardized manual muscle testing (paralysis/paresis/normal) for quadriceps and anterior tibialis muscles.
[Time Frame: 4th hours, 8th hours, 12th hours, 24th hours, 48th hours]

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Ahmet Murat Yayık, m_yayik@hotmail.com

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

10 oktober 2023

Primaire voltooiing (Werkelijk)

10 januari 2024

Studie voltooiing (Werkelijk)

6 februari 2026

Studieregistratiedata

Eerst ingediend

22 mei 2026

Eerst ingediend dat voldeed aan de QC-criteria

10 juni 2026

Eerst geplaatst (Werkelijk)

12 juni 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

12 juni 2026

Laatste update ingediend die voldeed aan QC-criteria

10 juni 2026

Laatst geverifieerd

1 juni 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren